Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gabrilovich, D. I.
Right arrow Articles by Carbone, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gabrilovich, D. I.
Right arrow Articles by Carbone, D. P.
Clinical Cancer Research Vol. 5, 2963-2970, October 1999
© 1999 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function1

Dmitry I. Gabrilovich2, Tadao Ishida, Sorena Nadaf, Joyce E. Ohm and David P. Carbone

Department of Medicine and The Vanderbilt Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838

Inadequate function of dendritic cells (DCs) in tumor-bearing hosts is one mechanism of tumor escape from immune system control and may compromise the efficacy of cancer immunotherapy. Vascular endothelial growth factor (VEGF), produced by most tumors, not only plays an important role in tumor angiogenesis but also can inhibit the maturation of DCs from hematopoietic progenitors. Here, we investigate a novel combination of antiangiogenic and immunotherapy based on this dual role of VEGF. Two s.c. mouse tumor models were used: D459 cells, expressing mutant human p53; and MethA sarcoma with point mutations in the endogenous murine p53 gene. Therapy with anti-mouse VEGF antibody (10 µg i.p. twice a week over 4 weeks) was initiated when tumors became palpable. Treatment of established tumors with anti-VEGF antibody alone did not affect the rate of tumor growth. However, anti-VEGF antibody significantly improved the number and function of lymph node and spleen DCs in these tumor-bearing animals. To investigate the possible effects of this antibody on the immunotherapy of established tumors, tumor-bearing mice were immunized with DCs pulsed with the corresponding mutation-specific p53 peptides, together with injections of anti-VEGF antibody. Therapy with peptide-pulsed DCs alone resulted in considerable slowing of tumor growth but only during the period of treatment, and tumor growth resumed after the end of the therapy. Combined treatment with peptide-pulsed DCs and anti-VEGF antibody resulted in a prolonged and much more pronounced antitumor effect. This effect was associated with the induction of significant anti-p53 CTL responses only in this group of mice. These data suggest that inhibition of VEGF may be a valuable adjuvant in the immunotherapy of cancer.




This article has been cited by other articles:


Home page
 VASC ENDOVASCULAR SURGHome page
D. M. Birk, J. Barbato, L. Mureebe, and R. A. Chaer
Basic Science Review: Current Insights on the Biology and Clinical Aspects of VEGF Regulation
Vascular and Endovascular Surgery, December 1, 2009; 42(6): 517 - 530.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
M. Z. Noman, S. Buart, J. Van Pelt, C. Richon, M. Hasmim, N. Leleu, W. M. Suchorska, A. Jalil, Y. Lecluse, F. El Hage, et al.
The Cooperative Induction of Hypoxia-Inducible Factor-1{alpha} and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis
J. Immunol., March 15, 2009; 182(6): 3510 - 3521.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Ko, A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al.
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Clin. Cancer Res., March 15, 2009; 15(6): 2148 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, S.-S. Ou, L. Archer, J. N. Atkins, J. Picus, P. Czaykowski, et al.
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
J. Clin. Oncol., November 20, 2008; 26(33): 5422 - 5428.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, et al.
First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma
Ann. Onc., August 1, 2008; 19(8): 1470 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sosman, C. Carrillo, W. J. Urba, L. Flaherty, M. B. Atkins, J. I. Clark, J. Dutcher, K. A. Margolin, J. Mier, J. Gollob, et al.
Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma
J. Clin. Oncol., May 10, 2008; 26(14): 2292 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Duluc, Y. Delneste, F. Tan, M.-P. Moles, L. Grimaud, J. Lenoir, L. Preisser, I. Anegon, L. Catala, N. Ifrah, et al.
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
Blood, December 15, 2007; 110(13): 4319 - 4330.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Tian, S. Grimaldo, M. Fugita, J. Cutts, N. L. Vujanovic, and L.-Y. Li
The Endothelial Cell-Produced Antiangiogenic Cytokine Vascular Endothelial Growth Inhibitor Induces Dendritic Cell Maturation
J. Immunol., September 15, 2007; 179(6): 3742 - 3751.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Talmadge
Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy
Clin. Cancer Res., September 15, 2007; 13(18): 5243 - 5248.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Fricke, N. Mirza, J. Dupont, C. Lockhart, A. Jackson, J.-H. Lee, J. A. Sosman, and D. I. Gabrilovich
Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses
Clin. Cancer Res., August 15, 2007; 13(16): 4840 - 4848.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, G. Merola, T. Gelardi, L. Racioppi, G. Fontanini, S. De Placido, et al.
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
PNAS, July 24, 2007; 104(30): 12468 - 12473.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF
Blood, July 15, 2007; 110(2): 624 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Ochoa, A. H. Zea, C. Hernandez, and P. C. Rodriguez
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 721s - 726s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini and W.K. Rathmell
Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 741s - 746s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Li, A. S. Lalani, T. C. Harding, B. Luan, K. Koprivnikar, G. Huan Tu, R. Prell, M. J. VanRoey, A. D. Simmons, and K. Jooss
Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF-Secreting Cancer Immunotherapy.
Clin. Cancer Res., November 15, 2006; 12(22): 6808 - 6816.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Lizee, L. G. Radvanyi, W. W. Overwijk, and P. Hwu
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms.
Clin. Cancer Res., August 15, 2006; 12(16): 4794 - 4803.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
J. A. Schmidt, J. M. de Avila, and D. J. McLean
Effect of Vascular Endothelial Growth Factor and Testis Tissue Culture on Spermatogenesis in Bovine Ectopic Testis Tissue Xenografts
Biol Reprod, August 1, 2006; 75(2): 167 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. F. Voelkel, R. W. Vandivier, and R. M. Tuder
Vascular endothelial growth factor in the lung
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L209 - L221.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. W. B. Jeffes, J. G. Zhang, N. Hoa, A. Petkar, C. Delgado, S. Chong, A. Obenaus, R. Sanchez, S. Khalaghizadeh, T. Khomenko, et al.
Antiangiogenic Drugs Synergize with a Membrane Macrophage Colony-Stimulating Factor-Based Tumor Vaccine to Therapeutically Treat Rats with an Established Malignant Intracranial Glioma
J. Immunol., March 1, 2005; 174(5): 2533 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Mazzolini, C. Alfaro, B. Sangro, E. Feijoo, J. Ruiz, A. Benito, I. Tirapu, A. Arina, J. Sola, M. Herraiz, et al.
Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas
J. Clin. Oncol., February 10, 2005; 23(5): 999 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Peterson, S. Swiger, W. M. Stadler, M. Medved, G. Karczmar, and T. F. Gajewski
Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma
Clin. Cancer Res., June 15, 2004; 10(12): 4048 - 4054.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Sandler, D. H. Johnson, and R. S. Herbst
Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer
Clin. Cancer Res., June 15, 2004; 10(12): 4258S - 4262S.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. S. Herbst and A. B. Sandler
Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?
Oncologist, June 1, 2004; 9(suppl_1): 19 - 26.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. X. Chen
Expanding the Clinical Development of Bevacizumab
Oncologist, June 1, 2004; 9(suppl_1): 27 - 35.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Melani, C. Chiodoni, G. Forni, and M. P. Colombo
Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity
Blood, September 15, 2003; 102(6): 2138 - 2145.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich
All-trans-Retinoic Acid Eliminates Immature Myeloid Cells from Tumor-bearing Mice and Improves the Effect of Vaccination
Cancer Res., August 1, 2003; 63(15): 4441 - 4449.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Ohm, D. I. Gabrilovich, G. D. Sempowski, E. Kisseleva, K. S. Parman, S. Nadaf, and D. P. Carbone
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Blood, June 15, 2003; 101(12): 4878 - 4886.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Yang and E. C. Lattime
Tumor-induced Interleukin 10 Suppresses the Ability of Splenic Dendritic Cells to Stimulate CD4 and CD8 T-Cell Responses
Cancer Res., May 1, 2003; 63(9): 2150 - 2157.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Zhang, N. Yang, J.-R. Conejo Garcia, A. Mohamed, F. Benencia, S. C. Rubin, D. Allman, and G. Coukos
Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma
Am. J. Pathol., December 1, 2002; 161(6): 2295 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Inoshima, Y. Nakanishi, T. Minami, M. Izumi, K. Takayama, I. Yoshino, and N. Hara
The Influence of Dendritic Cell Infiltration and Vascular Endothelial Growth Factor Expression on the Prognosis of Non-Small Cell Lung Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3480 - 3486.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. P. Gray, P. Arosio, and P. Hersey
Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells
Blood, May 1, 2002; 99(9): 3326 - 3334.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich
Chronic Myelogenous Leukemia
Hematology, January 1, 2002; 2002(1): 111 - 135.
[Abstract] [Full Text]

Home page
 BloodHome page
Z. Dembic, J.-A. Rottingen, J. Dellacasagrande, K. Schenck, and B. Bogen
Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level
Blood, May 1, 2001; 97(9): 2808 - 2814.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.